Bahl & Gaynor’s Phibro Animal Health PAHC Stock Holding History

Bahl & Gaynor’s Portfolio PAHC Stock Details PAHC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-45,980	Closed	-$980K	–	363
2019 Q3	$980K	Buy	45,980 +15	+0%	+$411	0.01%	274
2019 Q2	$1.46M	Sell	45,965 -38,182	-45%	-$1.2M	0.01%	252
2019 Q1	$2.78M	Buy	84,147 +2,343	+3%	+$72.9K	0.03%	187
2018 Q4	$2.63M	Buy	81,804 +2,646	+3%	+$99.8K	0.03%	171
2018 Q3	$3.4M	Buy	79,158 +21,334	+37%	+$1.01M	0.04%	158
2018 Q2	$2.66M	Buy	+57,824	New	+$2.56M	0.03%	190

Other funds holding PAHC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bahl & Gaynor's PAHC Position: Q4 2019 in Review

Bahl & Gaynor sold out of Phibro Animal Health (PAHC) in Q4 2019, closing a stake of 45,980 shares — an estimated $980K sold.

Bahl & Gaynor first reported a position in PAHC in Q2 2018 and held it in 6 quarters. The position peaked at $3.4M in Q3 2018. 155 funds tracked by Wall St. Rank hold PAHC as of Q4 2019.

Bahl & Gaynor reported no remaining Phibro Animal Health position as of Q4 2019 after selling out during the quarter.
Bahl & Gaynor sold 45,980 Phibro Animal Health shares in Q4 2019, an estimated $980K.
Bahl & Gaynor first reported a position in Phibro Animal Health in Q2 2018 and held it in 6 quarters.
Bahl & Gaynor's Phibro Animal Health position peaked at $3.4M in Q3 2018.
155 funds tracked by Wall St. Rank held Phibro Animal Health as of Q4 2019.

Based on Bahl & Gaynor's 13F filing for Q4 2019, filed 14 Feb 2020.